Hong Kong IsletRx patent announced by NLS Pharmaceutics (NLSPW)

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. furnished a report describing a new press release issued on September 4, 2025. The press release announces that NLS Pharmaceutics and Kadimastem have a Hong Kong patent covering a cell-selection and enrichment technology for IsletRx, a treatment approach aimed at diabetes patients. The 6-K mainly serves to provide this press release to investors as Exhibit 99.1.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of September 2025

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

CONTENTS

On September 4, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients.” A copy of this press release is furnished herewith as Exhibit 99.1.

1

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: September 4, 2025	By:	/s/ Alexander Zwyer
		Name:	Alexander Zwyer
		Title:	Chief Executive Officer

3

FAQ

What did NLS Pharmaceutics (NLSPW) disclose in this Form 6-K?

NLS Pharmaceutics disclosed that it issued a press release announcing a Hong Kong patent covering cell-selection and enrichment technology for IsletRx for diabetes patients, furnished as Exhibit 99.1.

What is the subject of the NLS Pharmaceutics and Kadimastem press release?

The press release is titled “NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients.”

Which patent jurisdiction is mentioned in the NLS Pharmaceutics 6-K filing?

The filing mentions a patent in Hong Kong covering cell-selection and enrichment technology related to IsletRx for diabetes patients.

How is the press release made available in the NLS Pharmaceutics 6-K?

The press release is included as Exhibit 99.1 to the Form 6-K, allowing investors to access the full text as part of the filing exhibits.

Who signed the NLS Pharmaceutics (NLSPW) Form 6-K?

The Form 6-K was signed on behalf of NLS Pharmaceutics Ltd. by Alexander Zwyer, the company’s Chief Executive Officer.

Does this NLS Pharmaceutics 6-K include financial results or earnings data?

No, this Form 6-K focuses on furnishing a press release about a Hong Kong patent related to IsletRx and does not provide financial or earnings data in the excerpt provided.